Nabsys 2.0, LLC ("Nabsys"), a pioneer in Electronic Genome Mapping (EGM), today announced the publication of a new preprint ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

The discovery was made by Jennifer Doudna and her team at UC Berkeley's Innovative Genomics Institute.

Phase 1 trial shows CRISPR-based CTX310 durably reduces LDL cholesterol and triglycerides by silencing the ANGPTL3 gene in ...

The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...

FARGO, N.D. & CORALVILLE, Iowa-- (BUSINESS WIRE)--Sep 16, 2026-- ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

In November 2018, a Chinese biophysicist named He Jiankui announced to the world that he had successfully edited the germline ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...

Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA ...